SOX9 Antibody - #AF6330

(11)   (11)  
Product: SOX9 Antibody
Catalog: AF6330
Description: Rabbit polyclonal antibody to SOX9
Application: WB IHC IF/ICC IP
Reactivity: Human, Mouse, Rat, Monkey
Prediction: Pig, Horse, Sheep, Rabbit, Dog, Chicken, Xenopus
Mol.Wt.: 56kDa; 56kD(Calculated).
Uniprot: P48436
RRID: AB_2835186

View similar products>>

   Size Price Inventory
 100ul $280 In stock
 200ul $350 In stock

Lead Time: Same day delivery

For pricing and ordering contact:
Local distributors
Related Downloads
MSDS
Data Sheet
COA
Protocols
WB Handbook
IHC Protocol
IF/ICC Protocol

Product Info

Source:
Rabbit
Application:
WB 1:500-1:2000, IHC 1:50-1:200, IF/ICC 1:100-1:500, ip 1:200
*The optimal dilutions should be determined by the end user.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

Reactivity:
Human,Mouse,Rat,Monkey
Prediction:
Pig(100%), Horse(100%), Sheep(100%), Rabbit(100%), Dog(100%), Chicken(92%), Xenopus(92%)
Clonality:
Polyclonal
Specificity:
SOX9 Antibody detects endogenous levels of total SOX9.
RRID:
AB_2835186
Cite Format: Affinity Biosciences Cat# AF6330, RRID:AB_2835186.
Conjugate:
Unconjugated.
Purification:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
Storage:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
Alias:

Fold/Unfold

campomelic dysplasia autosomal sex reversal; CMD 1; CMD1; CMPD 1; CMPD1; SOX 9; Sox9; SOX9_HUMAN; SRA 1; SRA1; SRXX2; SRXY10; SRY (sex determining region Y) box 9 (campomelic dysplasia autosomal; SRY (sex determining region Y) box 9; SRY (sex determining region Y)-box 9; SRY (sex-determining region Y)-box 9 protein; SRY related HMG box gene 9; Transcription factor SOX 9; Transcription factor SOX-9; transcription factor SOX9;

Immunogens

Immunogen:
Uniprot:

P48436(SOX9_HUMAN) >>Visit HPA database.

Gene(ID):
SOX9(6662)
Description:
SOX9 Plays an important role in the normal skeletal development. May regulate the expression of other genes involved in chondrogenesis by acting as a transcription factor for these genes. Defects in SOX9 are the cause of campomelic dysplasia (CMD1).
Sequence:
MNLLDPFMKMTDEQEKGLSGAPSPTMSEDSAGSPCPSGSGSDTENTRPQENTFPKGEPDLKKESEEDKFPVCIREAVSQVLKGYDWTLVPMPVRVNGSSKNKPHVKRPMNAFMVWAQAARRKLADQYPHLHNAELSKTLGKLWRLLNESEKRPFVEEAERLRVQHKKDHPDYKYQPRRRKSVKNGQAEAEEATEQTHISPNAIFKALQADSPHSSSGMSEVHSPGEHSGQSQGPPTPPTTPKTDVQPGKADLKREGRPLPEGGRQPPIDFRDVDIGELSSDVISNIETFDVNEFDQYLPPNGHPGVPATHGQVTYTGSYGISSTAATPASAGHVWMSKQQAPPPPPQQPPQAPPAPQAPPQPQAAPPQQPAAPPQQPQAHTLTTLSSEPGQSQRTHIKTEQLSPSHYSEQQQHSPQQIAYSPFNLPHYSPSYPPITRSQYDYTDHQNSSSYYSHAAGQGTGLYSTFTYMNPAQRPMYTPIADTSGVPSIPQTHSPQHWEQPVYTQLTRP

Predictions

Predictions:

Score>80(red) has high confidence and is suggested to be used for WB detection. *The prediction model is mainly based on the alignment of immunogen sequences, the results are for reference only, not as the basis of quality assurance.

Species
Results
Score
Pig
100
Horse
100
Sheep
100
Dog
100
Rabbit
100
Xenopus
92
Chicken
92
Bovine
0
Zebrafish
0
Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence

PTMs - P48436 As Substrate

Site PTM Type Enzyme
T11 Phosphorylation
S30 Phosphorylation
T43 Phosphorylation
T46 Phosphorylation
K61 Acetylation
S64 Phosphorylation P17612 (PRKACA)
K68 Ubiquitination
S78 Phosphorylation
K82 Ubiquitination
K122 Ubiquitination
K137 Ubiquitination
K141 Acetylation
K141 Ubiquitination
Y172 Phosphorylation
K173 Ubiquitination
S181 Phosphorylation P17612 (PRKACA) , Q13237 (PRKG2) , Q13464 (ROCK1)
T196 Phosphorylation
S199 Phosphorylation
S211 Phosphorylation
S214 Phosphorylation
S223 Phosphorylation
T236 Phosphorylation
T239 Phosphorylation
T240 Phosphorylation
K249 Ubiquitination
K253 Acetylation
K398 Acetylation
S414 Phosphorylation
Y442 Phosphorylation

Research Backgrounds

Function:

Transcriptional regulator that plays a role in chondrocytes differentiation and skeletal development. Binds to the COL2A1 promoter and activates COL2A1 expression, as part of a complex with ZNF219 (By similarity).

PTMs:

Ubiquitinated. Ubiquitination leads to proteasomal degradation and is negatively regulated by DDRGK1.

Subcellular Location:

Nucleus.

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
Subunit Structure:

Interacts (via C-terminus) with ZNF219. Interacts with DDRGK1.

Research Fields

· Environmental Information Processing > Signal transduction > cAMP signaling pathway.   (View pathway)

References

1). Plasma Membrane-Derived Biomimetic Apoptotic Nanovesicles Targeting Inflammation and Cartilage Degeneration for Osteoarthritis. Small methods, 2024 (PubMed: 39036830) [IF=12.4]
2). A lithium-containing biomaterial promotes chondrogenic differentiation of induced pluripotent stem cells with reducing hypertrophy. Stem Cell Research & Therapy, 2020 (PubMed: 32085810) [IF=7.5]

Application: IF/ICC    Species: Human    Sample: iPSCs

Fig. 7 The chondrogenic differentiation of iPSCs with different Li+ ions concentration in 14 days. a Immunofluorescence of chondrocytes specified proteins (COL II, Aggrecan, and SOX9) and hypertrophic specified protein (COL X and MMP13). b The average fluorescence intensity of COL II, Aggrecan, SOX9, MMP13, and COL X proteins in each group, n = 5. c The relative genes expression of chondrogenic differentiation cultured with Li+ ions, n = 3. d The relative genes expression of hypertrophic differentiation cultured with Li+ ions, n = 3. Data presented as mean ± SEM. Scale bar = 200 μm. CTR: MCDM without any Li+ ions. *p < 0.05, **p < 0.01, ***p < 0.001
3). Vitamin K2 ameliorates osteoarthritis by suppressing ferroptosis and extracellular matrix degradation through activation GPX4's dual functions. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2024 (PubMed: 38759289) [IF=7.5]

Application: WB    Species: Rat    Sample:

Fig. 8. GPX4 inhibitor RSL3 substantially attenuates VK2 protection of chondrocytes. (A-I) WB results for GPX4, NFκB, pMAPK/MAPK, Aggrecan, CollagenⅡ, SOX9, MMP3, MMP13 and Tubulin; (J) Quantitive analysis of relative Glutathione Peroxidase Activity; (K-L) GSH contents and ratio of GSH/GSSG; (M) Quantitative results of MDA content assay.
4). Asiatic acid attenuates hypertrophic and fibrotic differentiation of articular chondrocytes via AMPK/PI3K/AKT signaling pathway. ARTHRITIS RESEARCH & THERAPY, 2020 (PubMed: 32398124) [IF=4.9]
5). Hypoxia-inducible factor prolyl hydroxylase inhibitor alleviates heatstroke-induced acute kidney injury by activating BNIP3-mediated mitophagy. FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2024 (PubMed: 38865198) [IF=4.8]
6). Ddit3 suppresses the differentiation of mouse chondroprogenitor cells. INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2016 (PubMed: 27845261) [IF=4.0]

Application: WB    Species: mouse    Sample:

Fig. 5. Effects of C/EBP and Sox9 on the differentiation of ATDC5. (a and d) Relative mRNA levels of Sox9 and C/EBP in three groups. (b and c) Detection and quantification of Sox9 by Western blot and image J. (e and f) Detection and quantification of C/EBP by Western blot and image J. All data were expressed as means ± SD. *p < 0.05, **p < 0.01, ***p < 0.0001, compared to scrambled group. t
7). Region-specific effects of blocking estrogen receptors on longitudinal bone growth. JOURNAL OF ENDOCRINOLOGY, 2021 (PubMed: 34014834) [IF=4.0]
8). Fatty acid binding protein 3 deficiency limits atherosclerosis development via macrophage foam cell formation inhibition. EXPERIMENTAL CELL RESEARCH, 2021 (PubMed: 34370993) [IF=3.7]

Application: WB    Species: Mice    Sample: macrophages

Fig. 3. FABP3 knockdown reduced macrophage foam cell formation. Murine peritoneal macrophages were maintained in the special culture medium at 37 ◦C in a 5 % CO2 atmosphere. The cells were infected with lentivirus carrying shFABP3 or shRNA NC for 24 h and subsequently exposed with ox-LDL (50 μg/ml) for 24 h. (A) Representative Oil Red O-stained images of macrophages and quantification of the staining. (B) Immunoblots of SRA1, CD36, SRB1, ABCA1, and ABCG1 in macrophages. (C) Quantification of relative mRNA expression of SRA1, CD36, SRB1, ABCA1, and ABCG1. **p < 0.01 denote significant differences between the Control and the ox-LDL groups, &&p < 0.01 denote significant differences between the ox-LDL shRNA NC and ox-LDL + shFABP3 groups.
9). Impaired proliferation of growth plate chondrocytes in a model of osteogenesis imperfecta. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2022 (PubMed: 35561582) [IF=3.1]
10). Effect of tissue expansion on chondrocyte sheets in cartilage composite reconstruction. American Journal of Translational Research, 2023 (PubMed: 35035686) [IF=2.2]

Application: WB    Species: Rat    Sample:

Figure 8 Evaluation of protein expression and cartilage-related genes in the chondrocyte sheets cultured in vitro under static pressure and hypoxic conditions. (A) Protein expression of Aggrecan, COL II, Sox-9, and HIF-1α as determined using western blotting; β-actin was used as a loading control. The expression of Aggrecan (B), COL II (C), Sox-9 (D) and HIF1-α (E) genes was determined using real-time PCR. GAPDH was used as a housekeeping gene. Data are presented as the mean ± standard deviation (n=3), *P
Load more

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.